Professor Malhi and colleagues (2019) have raised questions about transcranial magnetic stimulation (TMS). However, the Royal Australian and New Zealand College of Psychiatrists (RANZCP) provides an excellent Position Statement and Professional Practice Guidelines on TMS and, in my view, TMS is arguably the most important advance in the treatment of major depressive disorder (MDD) since the introduction of imipramine (discovered in 1951; released in 1957) . There have been 30 randomized controlled trials, naturalistic studies and metaanalyses which prove that TMS is effective in the treatment of MDD. When evaluating the efficacy of TMS, it must be remembered that, to date, this treatment has only been available to patients who have failed psychotherapy and medication -that is, to people with treatment-resistant depression.
TMS was fist demonstrated to be effective in the treatment of MDD in the last decade of the 20th century. It has already been held in the wings three times longer than imipramine.
The reasons TMS is not used more widely are various -the equipment is expensive (by psychiatric standards) and a trained TMS operative (generally a highly competent nurse) needs to be in continuous attendance. At least one informed psychiatrist must be available for every TMS service to assist referring psychiatrists, determine dosage and treatment protocols, and supervise/authorize treatment. Usually, 20 daily treatments are provided (this will be revisited below). Using current stimulation protocols, probably less than 10 patients can be treated per machine per day. The next-generation stimulation protocol (theta-burst) will increase this output five-to sevenfold, but implementation will not be immediate. Malhi et al. (2019) describe the treatment of a woman of 50 years with a long history of MDD. She was first treated with medication, then electroconvulsive therapy (ECT) and then a long course of TMS. This treatment was unsuccessful, and the authors ask, 'Was it logical to prescribe rTMS after ECT?'.
ECT has a heavy side-effects burden. With a view to reducing this burden, 20 years ago, Pridmore (2000) compared two groups of patients with MDD: one received 2 weeks of three ECT sessions per week and the other received 2 weeks of one ECT session followed by four daily TMS sessions. Both groups improved and there was no significant difference in the degree of improvement. But the patients who received the combination treatment experienced fewer side-effects than those who received the course of six ECT sessions. Cristancho et al. (2013) reported a case series of patients who responded to ECT but could not tolerate maintenance ECT. Following an acute course of ECT, these patients were given maintenance TMS. This proved to be safe and effective treatment.
The RANZCP Position statement opines that TMS and ECT treatments do 'not generally occur concurrently'. However, in my experience variations of the above two studies are employed in clinical practice. Thus, in my opinion it was 'logical' for TMS to be provided following ECT. Malhi et al. (2019) questioned whether 'benzodiazepines may ... attenuate response to rTMS'. Should this be so, TMS could only be responsibly provided after any benzodiazepine was withdrawn (a potentially lengthy, problematic process). The concern that benzodiazepines might be a contraindication to TMS has been raised over the last two decades, building out of the belief that benzodiazepines decrease the efficacy of ECT (ECT and TMS have different actions). There is no convincing evidence that benzodiazepines are a contraindication to TMS.
Recently, Hunter et al. (2019) reported the outcome of 181 patients with MDD treated with TMS who were already receiving medication. Almost one third of these patients were receiving a stimulant and just over one third of patients were receiving a benzodiazepine. It was found that concomitant benzodiazepine use was associated with a slight improvement, whereas concomitant stimulant use was associated with a greater improvement.
Patients who receive very different drugs, it is reasonable to suppose, have different mental state features.
Patients with different mental state
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Discipline of Psychiatry, School of Medicine, University of Tasmania, Australia, Hobart, TAS, Australia features have different pathophysiology, which leads to different prognoses and responses to treatment. That patients taking benzodiazepines do not respond as well as those taking other medications is likely a consequence of a confounding factor (the reason the patients are taking benzodiazepines in the first place). There is no indication here of a causal relationship. Of course, stimulants have an antidepressant action and benzodiazepines do not.
More recently, when a large group of patients with MDD were treated with TMS, four response trajectories were described. An association was found between poorer response and benzodiazepine use. On this basis, the authors suggested that 'clinicians should consider discontinuing even lowdose benzodiazepines, if possible, before pursuing rTMS treatment'. I do not believe this approach is justified. Again, the authors are reporting a correlation and no proof of cause. As Professor Mark S George, Editor of Brain Stimulation, stated in personal communication, 'Big belts don't cause obesity, although they are correlated'. Malhi et al. (2019) raise the question of whether concomitant anxiety is an indicator of poor response to TMS. In a recent 248-patient nonblinded study, Clarke et al. (2019) found TMS to be effective in MDD with comorbid anxiety. Malhi et al. (2019) report that the patient they described received 30 treatments (funded by the public system), then another 10 treatments (self-funded; for a total of 40) and then a further 10 treatments were recommended -'but the patient refused'. We are not informed of the role of the recommender. These authors ask, 'Was the number of rTMS sessions prescribed appropriate?'.
It is not possible to comprehensively answer this question without further clinical information and greater word and references freedom. However, around the world, a common strategy is to commence with 20 daily treatments. On completion, if no progress has been made, treatment is ceased. When remission has not been achieved, but there is clear evidence of response, a further 10 treatments may be provided (for a total of 30). Some US facilities have provided 36 treatments. It is easy to make (and follow) rules when patients improve, but when the suffering patient is relatively unresponsive, the treating psychiatrist may feel obligated to go an extra yard. It is noted that the patient under discussion received 14 ECT (which may be outside some guidelines and would cause most psychiatrists to worry) and this was followed by maintenance ECT. Malhi et al. (2019) ask whether 'the financial cost of rTMS to the health system and the patient were justified'. This is an easy question because we know the patient did not respond. However, if she had gone into remission by the 40th treatment session (which is possible), with the suffering over, all would agree that all monies had been well spent.
The real question is whether TMS represents value for money? At first glance, it would appear that TMS (20 treatments per course) would be more expensive than ECT (6-8 treatments per course). But this is not so -TMS does not require the services of anaesthetists, anaesthetic nurses or recovery room staff (among a range of factors). And who pays the cost of ECT side-effects?
TMS is effective in a proportion of patients with treatment-resistant depression. Finally, an overdose of imipramine may be fatal, an overdose of TMS will not.
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